BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 25456955)

  • 1. Expression of the embryonic morphogen Nodal in differentiated thyroid carcinomas: Immunohistochemistry assay in tissue microarray and The Cancer Genome Atlas data analysis.
    Chai YJ; Kim YA; Jee HG; Yi JW; Jang BG; Lee KE; Park YJ; Youn YK
    Surgery; 2014 Dec; 156(6):1559-67; discussion 1567-8. PubMed ID: 25456955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
    Pool C; Walter V; Bann D; Goldenberg D; Broach J; Hennessy M; Cottrill E; Washburn E; Williams N; Crist H; Imamura Y; Warrick JI
    Virchows Arch; 2019 Mar; 474(3):341-351. PubMed ID: 30645670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Follicular cell (papillary and follicular) thyroid carcinoma, genetic inheritance, and molecular diagnostic markers].
    Kazubskaia TP; Kozlova VM; Kondrat'eva TT; Pavlovskaia AI; Marakhonov AV; Baranova AV; Ivanova NI; Stepanova AA; Poliakov AV; Belev NF; Brzhezovskiĭ VZh
    Arkh Patol; 2014; 76(5):3-12. PubMed ID: 25543402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Testing for Oncogenic Gene Alterations in Pediatric Thyroid Lesions.
    Mostoufi-Moab S; Labourier E; Sullivan L; LiVolsi V; Li Y; Xiao R; Beaudenon-Huibregtse S; Kazahaya K; Adzick NS; Baloch Z; Bauer AJ
    Thyroid; 2018 Jan; 28(1):60-67. PubMed ID: 29108474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
    Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
    APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications.
    Guo Z; Hardin H; Montemayor-Garcia C; Asioli S; Righi A; Maletta F; Sapino A; Lloyd RV
    Endocr Pathol; 2015 May; 26(2):157-63. PubMed ID: 25771986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follicular variant of papillary thyroid carcinoma with B-type Raf(V600E) showing higher frequency of suspicious sonographic features and multifocality.
    Shin DY; Kim KJ; Chang S; Kim H; Hwang S; Kim W; Bae J; Park S; Kang SW; Chung WY; Lee EJ
    Head Neck; 2015 Nov; 37(11):1590-5. PubMed ID: 24909403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
    Zimmermann AK; Camenisch U; Rechsteiner MP; Bode-Lesniewska B; Rössle M
    Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
    An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
    Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.
    Wobker SE; Kim LT; Hackman TG; Dodd LG
    Cancer Cytopathol; 2015 Sep; 123(9):531-9. PubMed ID: 26080065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of BRAF V600E mutation in different thyroid lesions].
    Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?
    Lassalle S; Hofman V; Ilie M; Bonnetaud C; Puisségur MP; Brest P; Loubatier C; Guevara N; Bordone O; Cardinaud B; Lebrigand K; Rios G; Santini J; Franc B; Mari B; Al Ghuzlan A; Vielh P; Barbry P; Hofman P
    Endocr Relat Cancer; 2011 Oct; 18(5):579-94. PubMed ID: 21778212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility.
    Simms A; Jacob RP; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2016 Jan; 44(1):26-31. PubMed ID: 26481593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
    Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
    Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.
    Lamba Saini M; Weynand B; Rahier J; Mourad M; Hamoir M; Marbaix E
    Diagn Pathol; 2015 Apr; 10():32. PubMed ID: 25907675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts.
    Wallander M; Layfield LJ; Jarboe E; Emerson L; Liu T; Thaker H; Holden J; Tripp S
    Appl Immunohistochem Mol Morphol; 2010 May; 18(3):231-5. PubMed ID: 20042852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.
    Chung KW; Yang SK; Lee GK; Kim EY; Kwon S; Lee SH; Park DJ; Lee HS; Cho BY; Lee ES; Kim SW
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):660-6. PubMed ID: 17054470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
    Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
    Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
    Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
    Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data.
    Chai YJ; Yi JW; Jee HG; Kim YA; Kim JH; Xing M; Lee KE
    PLoS One; 2016; 11(7):e0159235. PubMed ID: 27410688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.